Optimeos
optimeos.com
Health Care
Biologics & Biosimilars
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
501-1000
employees, estimated range
Grants
$2.6M
7 grants · CORDIS
Backers
1
Anzu Partners
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 19, 2025
Won a grant $300k · CORDIS
Apr 9, 2024
Won a grant $300k · CORDIS
Jul 15, 2023
Won a grant $1M · CORDIS
Jun 1, 2022
Won a grant $288k · CORDIS
Sep 5, 2021
Won a grant $255k · CORDIS
Dec 15, 2020
Won a grant $256k · CORDIS
Feb 1, 2019
Won a grant $225k · CORDIS
Funding rounds
Backed byfrom the funds' portfolios and accelerator catalogs
Anzu Partners Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Trellis Bioscience is developing native human antibodies to disrupt bacterial biofilms and address difficult-to-treat infections.
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality.
Angitia is a clinical-stage biotechnology company focused on discovering and developing breakthrough therapeutics that address the key…
Neurolieve Biosciences is developing NLV-01, a first-in-class, non-opioid biologic designed to silence neuropathic pain and trigger…
Lighthouse Pharma is a clinical stage private biopharmaceutical company pioneering precision medicine approaches to major unmet medical…
"We are committed to creating the future of oncology by developing innovative therapies inducing autophagy to address unmet medical needs".
News
Hatch BioFund Invests In Optimeos Life Sciences To Advance Nanoparticle Drug Delivery Platform
Hatch BioFund announced an investment in Optimeos Life Sciences, a Princeton University spinout developing a proprietary nanoparticle platform for the intracellular delivery of therapeutic macromolecules, including RNA, DNA, and proteins.
Read more
Report
Hatch BioFund Announces Investment in Optimeos Life Sciences to Advance Novel Nanoparticle Platform for the Delivery of Therapeutic Nucleic Acids and Proteins
DOYLESTOWN, Pa. & PRINCETON, N.J., June 25, 2026--Hatch BioFund, an early-stage life sciences venture capital firm headquartered at the Pennsylvania Biotechnology Center in Doylestown, PA ("Hatch"), today announced an investment in Optimeos Life Sciences,
Read more
Report
Hatch BioFund Announces Investment in Optimeos Life Sciences to Advance Novel Nanoparticle Platform for the Delivery of Therapeutic Nucleic Acids and Proteins - AOL
Read more
Report
Hatch BioFund Announces Investment in Optimeos Life Sciences to Advance Novel Nanoparticle Platform for the Delivery of Therapeutic Nucleic Acids and Proteins
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Princeton
United States
HQ
500-1000 est. staff